References
- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
- Kartal-Yandim M, Adan-Gokbulut A, Baran Y. Molecular mechanisms of drug resistance and its reversal in cancer. Crit Rev Biotechnol. 2016;36:716–726.
- Cagel M, Tesan FC, Bernabeu E, et al. Polymeric mixed micelles as nanomedicines: achievements and perspectives. Eur J Pharm Biopharm. 2017;113:211–228.
- Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst. 2003;20:357–403.
- Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2006;24:1–16.
- McClements DJ, Decker EA, Park Y, et al. Structural design principles for delivery of bioactive components in nutraceuticals and functional foods. Crit Rev Food Sci Nutr. 2009;49:577–606.
- Manjappa AS, Kumbhar PS, Disouza JI, et al. Polymeric mixed micelles: improving the anticancer efficacy of single-copolymer micelles. Crit Rev Ther Drug Carrier Syst. 2019;36:1–58.
- Shi CH, Zhang ZQ, Wang F, et al. Active-targeting docetaxel-loaded mixed micelles for enhancing antitumor efficacy. J Mol Liq. 2018;264:172–178.
- Zhu Y, Yu J, Tong S, et al. Preparation and in vitro evaluation of povidone-sodium cholate-phospholipid mixed micelles for the solubilization of poorly soluble drugs. Arch Pharm Res. 2010;33:911–917.
- Roy R, Kumar S, Tripathi A, et al. Interactive threats of nanoparticles to the biological system. Immunol Lett. 2014;158:79–87.
- Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615–1626.
- Pellosi DS, d'Angelo I, Maiolino S, et al. In vitro/in vivo investigation on the potential of Pluronic® mixed micelles for pulmonary drug delivery. Eur J Pharm Biopharm. 2018;130:30–38.
- Jin X, Yang Q, Cai N. Preparation of ginsenoside compound-K mixed micelles with improved retention and antitumor efficacy. IJN. 2018;13:3827–3838.
- Kapse-Mistry S, Govender T, Srivastava R, et al. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 2014;5:159.
- Zhao DJ, Zhang HY, Yang SF, et al. Redox-sensitive mPEG-SS-PTX/TPGS mixed micelles: an efficient drug delivery system for overcoming multidrug resistance. Int J Pharm. 2016;515:281–292.
- Zhang P, He WX, Zhang HY, et al. Multifunctional mixed micelles for efficient docetaxol delivery for cancer therapy. Chempluschem. 2016;81:1237–1244.
- Magee GA, French J, Gibbon B, et al. Bile salt/lecithin mixed micelles optimized for the solubilization of a poorly soluble steroid molecule using statistical experimental design. Drug Dev Ind Pharm. 2003;29:441–450.
- Brajtburg J, Elberg S, Travis SJ, et al. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Antimicrob Agents Chemother. 1994;38:294–299.
- Brajtburg J, Elberg S, Kobayashi GS, et al. Amphotericin B incorporated into egg lecithin-bile saltmixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses. Antimicrob Agents Chemother. 1994;38:300–306.
- Vogtherr M, Marx A, Mieden AC, et al. Investigation of solubilising effects of bile salts on an active pharmaceutical ingredient with unusual pH dependent solubility by NMR spectroscopy. Eur J Pharm Biopharm. 2015;92:32–41.
- Jin X, Zhou B, Xue L, et al. Soluplus(®) micelles as a potential drug delivery system for reversal of resistant tumor. Biomed Pharmacother. 2015;69:388–395.
- Linn M, Collnot EM, Djuric D, et al. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. Eur J Pharm Sci. 2012;45:336–343.
- Hou J, Sun E, Sun C, et al. Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus(®)-Solutol(®) HS15 binary mixed micelles system. Int J Pharm. 2016;512:186–193.
- Ke Z, Zhang Z, Wu H, et al. Optimization and evaluation of Oridonin-loaded Soluplus®-Pluronic P105 mixed micelles for oral administration. Int J Pharm. 2017;518:193–202.
- Zhao J, Xu Y, Wang C, et al. Soluplus/TPGS mixed micelles for dioscin delivery in cancer therapy. Drug Dev Ind Pharm. 2017;43:1197–1204.
- Narain PK, DeMaria EJ, Heuman DM. Lecithin protects against plasma membrane disruption by bile salts. J Surg Res. 1998;78:131–136.
- Tan Y, Qi J, Lu Y, et al. Lecithin in mixed micelles attenuates the cytotoxicity of bile salts in Caco-2 cells. Toxicol In vitro. 2013;27:714–720.
- Wang LL, He DD, Wang SX, et al. Preparation and evaluation of curcumin-loaded self-assembled micelles. Drug Dev Ind Pharm. 2018;44:563–569.
- Xu M, Mou YH, Hu MM, et al. Evaluation of micelles incorporated into thermosensitive hydrogels for intratumoral delivery and controlled release of docetaxel: a dual approach for in situ treatment of tumors. Asian J Pharm Sci. 2018;13:373–382.
- Tan L, Peng J, Zhao Q, et al. A novel MPEG-PDLLA-PLL copolymer for docetaxel delivery in breast cancer therapy. Theranostics. 2017;7:2652–2672.
- Zhang W, Shi Y, Chen YZ, et al. Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials. 2011;32:2894–2906.
- Hou J, Wang J, Sun E, et al. Preparation and evaluation of icarisideII-loaded binary mixed micelles using Solutol and Pluronic F127 carriers. Drug Deliv. 2016;23:3248–3256.
- Aguiar J, Carpena P, Molina-Bolívar JA, et al. On the determination of the critical micelle concentration by the pyrene 1:3 ratio method. J Colloid Interface Sci. 2003;258:116–122.
- Choe J, Lee SM, Lim S, et al. Doubling time of thymic epithelial tumours on CT: correlation with histological subtype. Eur Radiol. 2017;27:4030–4036.
- Jindal N, Mehta SK. Nevirapine loaded poloxamer 407/pluronic P123 mixed micelles: optimization of formulation and in vitro, evaluation. Coll Surf B Biointerf. 2015;129:100–106.
- Xue B, Wang Y, Tang X, et al. Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro. J Biomed Nanotechnol. 2012; 8:80–89.
- Hervella P, Dam JH, Thisgaard H, et al. Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with 57Co-porphyrin: oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. J Control Rel. 2018;291:11–25.
- Zhang H, Li RY, Lu X, et al. Docetaxel-loaded liposomes: preparation, pH sensitivity, pharmacokinetics, and tissue distribution. J Zhejiang Univ Sci B. 2012;13:981–989.
- Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2013;48:416–427.
- Anand U, Lu J, Loh D, et al. Hydration layer-mediated pairwise interaction of nanoparticles. Nano Lett. 2016;16:786–790.
- Li SD, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Rel. 2010;145:178–181.
- Gabizon A, Shmeeda H, Horowitz AT, et al. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev. 2004;56:1177–1192.
- Stylianopoulos T, Jain RK. Design considerations for nanotherapeutics in oncology. Nanomedicine. 2015;11:1893–1907.